Condition: Myelofibrosis · Moderate Thrombocytopenia · Mild Thrombocytopenia · Sponsor: Karyopharm Therapeutics Inc
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
This description comes directly from the study's public registry record.
Karyopharm Medical Information · (888) 209-9326 · clinicaltrials@karyopharm.com
Always discuss trial participation with your own doctor first.
| City of Hope - Duarte Main Site | Duarte, California, United States | Recruiting |
| Maryland Oncology Hematology - Independent of SCRI/ US Oncology | Columbia, Maryland, United States | Recruiting |
| Weill Cornell Medicine NewYork-Presbyterian | New York, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| MD Anderson | Houston, Texas, United States | Recruiting |
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
| UZ Gent | Ghent, Belgium | Recruiting |
| UZ Leuven - Campus Gasthuisberg | Leuven, Belgium | Recruiting |
| University Multiprofile Hospital for Active Treatment Sveti George - Base 1 | Plovdiv, Bulgaria | Recruiting |
| University Hospital Sv.Ivan Rilski - Sofia | Sofia, Bulgaria | Recruiting |
| University Multiprofile Hospital for Active Treatment Aleksandrovska | Sofia, Bulgaria | Recruiting |
+ 58 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05980806